Fennec Pharmaceuticals (TSX:FRX) FCF Margin %: 15.75% (As of Mar. 2026)

What is Fennec Pharmaceuticals FCF Margin %?

Fennec Pharmaceuticals TSX:FRX +1.76% 53 FCF Margin % is 15.75% as of Mar. 2026. GuruFocus rates TSX:FRX with a GF Score™ of 53/100 and a GF Value™ of C$14.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Fennec Pharmaceuticals ranks better than 67.36% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Fennec Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2026 was C$3.26 Mil. Fennec Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was C$20.73 Mil. Therefore, Fennec Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was 15.75%.

As of today, Fennec Pharmaceuticals's current FCF Yield % is -1.52%.

The historical rank and industry rank for Fennec Pharmaceuticals's FCF Margin % or its related term are showing as below:

TSX:FRX' s FCF Margin % Range Over the Past 10 Years
Min: -9163.3 Med: -80.66 Max: 56.75
Current: -11.31

During the past 13 years, the highest FCF Margin % of Fennec Pharmaceuticals was 56.75%. The lowest was -9163.30%. And the median was -80.66%.

TSX:FRX's FCF Margin % is ranked better than
67.36% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs TSX:FRX: -11.31

Fennec Pharmaceuticals FCF Margin % Related Terms

Fennec Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals FCF Margin % Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

0.00

-1,176.59

-80.66

56.75

-27.94

Fennec Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-49.34	-38.19	11.98	-43.28	15.75

TSX:FRX vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Fennec Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's FCF Margin % falls into.

Save Embed

53GF Score

Fennec Pharmaceuticals Inc TSX:FRX

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Fennec Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Fennec Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-17.207	/	61.584
	=	-27.94 %

Fennec Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	3.264	/	20.728
	=	15.75 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 15.75% mean?

Fennec Pharmaceuticals (TSX:FRX) has a FCF Margin % of 15.75% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fennec Pharmaceuticals and its competitors. According to the industry distribution chart, Fennec Pharmaceuticals ranks #313 out of 959 companies in the Biotechnology industry, placing it in the top 32.6%.

Is Fennec Pharmaceuticals' FCF Margin % too high?

Fennec Pharmaceuticals' current FCF Margin % is 15.75%. Based on the distribution chart, Fennec Pharmaceuticals ranks #313 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fennec Pharmaceuticals has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Fennec Pharmaceuticals' FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Fennec Pharmaceuticals ranks #313 out of 959 companies for FCF Margin %. This puts Fennec Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fennec Pharmaceuticals and its competitors. Fennec Pharmaceuticals's current FCF Margin % is 15.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Fennec Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Fennec Pharmaceuticals (TSX:FRX) is currently considered Fairly Valued. The stock's GF Value™ is C$14.13, compared to a current price of C$15.00 — trading 6.2% above its estimated fair value. The current FCF Margin % is 15.75%. Fennec Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Fennec Pharmaceuticals (TSX:FRX), the current FCF Margin % is 15.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (TSX:FRX) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of C$15.00 is trading 6.2% above its estimated GF Value™ of C$14.13. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSX:FRX:

FCF Margin %: 15.75%
GF Value™: C$14.13 vs. price of C$15.00 (6.2% above fair value)
GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the TSX:FRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies NEOE:HELP TSX:EPRX TSX:MSCL TSX:HBP NEOE:ONCO TSXV:SHRX XCNQ:QNTM TSXV:NRX XCNQ:TELI XCNQ:METX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges FENC:USA RV41:Germany

Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

53GF Score

Get the complete analysis for TSX:FRX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$15.00

Price

C$14.13

GF Value

View TSX:FRX Analysis

See FCF Margin % data for all stocks →